Market Overview:

Global T-Cell Therapy Market was valued at approximately USD 3.95 Billion in 2023. Over the course of the forecast period (2024–2031), the market is expected to develop at a compound annual growth rate (CAGR) of 35.33%, reaching a value of USD 36.86 Billion by 2031.

A number of businesses have changed their business models from developing small-molecule & protein-based therapies to adoptive therapies with the approval of tecartus, Yescarta, & Kymriah. Due to the fact that both public and private entities are making more strategic investments in this field, the market has grown. In the future years, there is anticipated to be more rivalry in the T-cell therapy market due to rising product approval rates and expanding manufacturing capabilities. As the first chimeric antigen receptor (CAR) T-cell therapy, Yescarta was approved by the U.S. FDA in February 2022 for the first care of large B-cell lymphoma (LBCL) that has relapsed or is resistant. With a Category 1 recommendation in the NCCN Treatment Guideline, Yescarta is the first CAR T-cell treatment. Furthermore, the FDA approved ciltacabtagene autoleucel (Carvykti) in February 2022 for patients with refractory multiple myeloma—that is, those who have not responded to treatment or have returned after treatment (relapsed).

Furthermore, research funding aimed at figuring out how T-cell treatments may be utilized to treat viral infections has increased as a result of the global COVID-19 epidemic. For example, Tevogen Bio announced in November 2022 that it intends to look into the possible therapeutic uses of TVGN-489, an investigational COVID-19 T cell therapy, in Long COVID. The purpose of the highly purified cytotoxic CD8+ T lymphocytes (CTLs) TVGN-489 is to locate and destroy SARS-CoV-2 infected cells.

Additionally, T-cell-based methods are currently widely applied in the field of cancer immunotherapy because of their higher success rate. Globally, more than 500 clinical trials examining the use of CAR-T cells to treat cancer have been conducted since March 2021. Of these, the majority are being conducted in East Asia, followed by the United States, and then Europe. This study demonstrates the growing significance of CAR treatments in the management of cancer. Furthermore, in order to improve their market position in the upcoming years, the majority of the major manufacturers are investing in CD19 CART-T treatments.

However, the expanding field of gene therapy plays a significant role in the effectiveness of CAR-T treatments. The market for gene therapy is probably going to keep expanding due to increased investment. For example, Ori Biotech raised over $100 million in Series B funding in January 2022 to launch a new platform for researching C&G therapies. For a number of chronic diseases, this funding facilitated a quick transition from precommercialization to market launch gene treatments.

Market Dynamics:

Market Drivers:

Advancements in Immunotherapy and Biotechnology

• The above T-Cell Therapy Market is driven by ongoing developments in biotechnology and immunotherapy, especially in the area of cellular immunotherapy. T-cell therapies, such as T-cell receptor (TCR) therapy and chimeric antigen receptor (CAR) T-cell therapy, use the immune system's strength to precisely and effectively target and eradicate cancer cells. Significant advancements in our knowledge of the intricate relationships between cancer cells as well as the immune system have been made during the last ten years, which have aided in the discovery of new therapeutic targets and the creation of ground-breaking T-cell-based immunotherapies. Genetically modified T cells with improved therapeutic properties, reduced toxicity, and improved persistence have been produced thanks to biotechnology advancements including technologies for gene editing (e.g., CRISPR-Cas9), lentiviral and also retroviral vector systems, as well as cell manufacturing processes. T-cell therapies are anticipated to be in greater demand as an appealing therapy for cancer patients as the field of immunotherapy continues to develop and mature due to continuing research, clinical trials, & regulatory approvals; this will drive market expansion in the T-Cell Therapy Market.

Clinical Success and Commercialization of T-Cell Therapies

• The market for T-cell therapy grows due to its rising clinical success and commercialization. Patients with solid tumors and hematologic malignancies are exhibiting amazing efficacy and persistent responses while using these therapies. In clinical trials and also real-world settings, CAR T-cell therapies, like axicabtagene ciloleucel (Yescarta) as well as tisagenlecleucel (Kymriah), have demonstrated high response rates or long-term remissions when used to treat acute lymphoblastic leukemia (ALL) and relapsed or refractory B-cell lymphomas. These treatments have received regulatory approval. Furthermore, the possibility of using TCR therapies to target solid tumor antigens, like neoantigens & cancer-testis antigens, is being investigated in ongoing clinical investigations and early-phase trials. This could broaden the application of T-cell therapies beyond hematological tumors. This has led to increased investment or commercialization efforts in the T-Cell Therapy Market.

Market Trends:

Expansion of Indications and Target Antigens

• The increasing number of target antigens and indications for T-cell treatments that are being investigated. T-cell therapies, such as CAR T-cell and TCR therapies, were first created for the treatment of hematologic malignancies such B-cell lymphomas and leukemias. To create T-cell therapies that can identify and eradicate malignant cells with high specificity as well as efficacy, clinical trials as well as preclinical research are investigating novel target antigens communicated on solid tumor cells, that include tumor-specific new antigens, cancer-testis antibodies, and overexpressed surface proteins. Furthermore, the discovery of patient-specific mutations or antigen profiles has been made easier by developments in genome sequencing & bioinformatics. This has made personalized T-cell therapy techniques possible that are customized to each patient's tumor antigens and immune responses. The market for T-cell therapy is experiencing innovation and diversification as a result of the growing understanding of the immunology of tumors and antigen recognition processes brought about by continuous research and clinical trials.

Emergence of Off-the-Shelf Allogeneic T-Cell Therapies

• The rise of commercially available allogeneic T-cell therapies as a possible substitute for autologous T-cell therapies in the T-Cell Therapy Market. Autologous T-cell therapies entail the extraction, modification, and reintroduction of a patient's own T cells. This might pose significant logistical, financial, and temporal constraints, especially for patients whose diseases are severe or advancing quickly. Allogeneic T-cell therapies, on the other hand, make use of donor-derived T cells that have undergone genetic modification to improve their safety, persistence, as well as compatibility with recipient immune systems. The result is that for the creation of "universal" or "off-the-shelf" cell therapies, which do not require customized manufacturing and can be given to multiple patients. The growth of universal donor cell lines with improved safety features, such as the removal of T-cell receptor (TCR) expression or the reduction of major histocompatibility complex ( MHC ) expression to reduce graft-versus-host disease (GVHD) as well as immune rejection, is made easier by advancements in genome editing technologies, a result as CRISPR-Cas9 and TALENs. Furthermore, the scalability, potency, & shelf-life of allogeneic T-cell therapies are being further improved by advancements in cell manufacturing procedures, cryopreservation methods, and immune-modulatory strategies.

Market Restraining Factors:

High Treatment Costs and Reimbursement Challenges​

• The high cost of T-cell therapy development, production, and administration can be a financial barrier to patient access and system acceptance. This is known as the T-Cell Therapy Market. The creation of T-cell therapies, such as CAR T-cell and TCR therapies, is mostly financed by the intricate and resource-intensive manufacturing processes involved in cell isolation, genetic engineering, expansion, and the standard control testing. The expense of producing T-cell therapy is further increased by the requirement for specialized facilities, tools, and knowledge for handling and processing cells. T-cell treatments are therefore very expensive, frequently costing over 0,000 each treatment, which puts a burden on patients, healthcare payers, and providers. Securing sufficient payment for T-cell therapy is also made more difficult by the fact that different insurance companies, governments, and healthcare systems have varied coverage choices and reimbursement procedures. Uncertainty and difficulties in getting sufficient compensation for T-cell treatments. T-cell therapy market access and reimbursement talks are made more difficult by the absence of established payment channels, coding systems, and value-based pricing models, which slows patient access and market penetration.

Segmentation Analysis:

The market is divided into segments based on By Therapy Type, By Indication.

By Therapy Type

Based on the Therapy Type of the market is Categorised into CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based.

The CAR-T therapies had the largest market share of 95.66% in 2022, thanks to the exponential increase in the number of clinical trials involving these treatments and the growing involvement of key firms. The market's dominance is being reinforced by the large number of new firms and academic institutions conducting clinical trials for CAR-T therapy products for both the same and distinct indications.

Advances in its production have led to an increase in the utilization of CAR-T treatments for various malignancies. New approaches, such as second- and next-generation CAR-T immunotherapy, can increase the production of organic income by overcoming obstacles including resistance and side effects.

On the other hand, due to their potential to treat solid tumors, T-cell receptor-based treatments are predicted to expand significantly at a CAGR of over 30% by 2030. This field is getting a lot of attention for melanoma treatment. Adaptimmune is one of the companies that specializes in TCR therapy for melanoma in collaboration with GlaxoSmithKline.

By Indication 

Based on the Indication of the market is segmented into Hematologic Malignancies, Solid Tumors, Others.

In 2022, hematological malignancies will account for nearly 50% of total revenue. CAR-T cell therapy has shown encouraging efficacy against several hematological malignancies since gaining initial FDA approval in 2017. It may even provide patients with severe conditions, such as B cell leukemia with acute lymphoblastic leukemia or lymphoma and with a curative treatment option. The two primary targets for CAR-T cell treatment that are currently licensed are B cell maturity antigen for multiple myeloma and CD19 for a range of lymphoid cancers, including B-ALL and diffuse large B-cell lymphoma (DLBCL). However, the category is expected to face fierce market rivalry in the upcoming years because to the entry of multiple major firms and the high fixed costs associated with generating autologous cells.

Solid tumors are expected to see significant market growth at a compound annual growth rate (CAGR) of more than 25% throughout the forecast period. Whether employed in conjunction with an mRNA vaccination or on its own, a novel chimeric antigen receptor (CAR) T-cell product demonstrated promising first results in patients with solid tumors. It was also judged to have an acceptable safety profile. However, because of difficulties with growth, persistence, and trafficking in addition to interactions with the aggressive tumor microenvironment, the therapy's use for patients with solid tumors (TME) is limited.

List of Companies Profiled:

• Novartis AG
• Merck KGaA
• Gilead Sciences Inc.
• Kite Pharma, Inc.
• Juno Therapeutics Inc.
• Pfizer Inc.
• Celgene Corporation
• bluebird bio, Inc.
• Adaptimmune Therapeutics plc
• Atara Biotherapeutics, Inc.
• Mustang Bio, Inc.
• TCR² Therapeutics Inc.
• Autolus Therapeutics plc
• Immunocore Limited
• Eureka Therapeutics, Inc.
• Ziopharm Oncology, Inc.
• Precision Biosciences Inc.
• Sorrento Therapeutics, Inc.
• Fate Therapeutics, Inc.
• Celyad Oncology SA
• Caribou Biosciences, Inc.

Key Industry Developments:

• In September 2022, Arsenal Biosciences, Inc. (ArsenalBio), a privately held business that specializes in programmable cell therapy and develops state-of-the-art CAR T therapies for solid tumors, today announced a multi-year collaboration with Genentech, a Roche Group company. The companies will employ high-throughput T cell engineering and screening using ArsenalBio's unique technology to identify critical success circuits for T cell-based therapies.

Report Coverage:

The report will cover the qualitative and quantitative data on the global T-Cell Therapy Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations:

Regional Snapshots:

By region, Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. In 2022, North America accounted for approximately 63.88% of the global T-cell therapy market revenue. Due in significant part to the country's robust commercial base, extensive clinical T-cell therapy research program, and robust research base, the United States has emerged as a dominant player in the global market. Significant market growth has also been generated by the increasing number of regulatory approvals for these medicines in the US and Canada, as well as by the shifting reimbursement environment in the area.

The Asia Pacific region is expected to grow at a rapid rate of more than 30% throughout the course of the projected period. Since China has the most registered clinical trials for CAR-T therapies, it has been a sought-after market for these therapies in recent years. The nation has grown significantly and has the highest compound annual growth rate in the Asia-Pacific area because to concentrated efforts on government expenditures and reforms.

T-Cell Therapy Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report:

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions:

• How much the global T-Cell Therapy Market valued?
• Which region has the largest share in 2024 for the global T-Cell Therapy Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of T-Cell Therapy Market:

• Historic year: 2018- 2021
• Base year: 2022
• Forecast: 2023 to 2031
• Representation of Market revenue in USD Million

T-Cell Therapy Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: